文献速递胃肠外科围术期管理与 ERAS

国产单孔与多孔机器人远端胃癌根治术近期疗效比较

[A comparative analysis of the short-term efficacy of single-port and multi-port robotic distal gastrectomy for gastric cancer: a propensity score matched cohort study].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2026-01-01

本研究为回顾性队列研究,纳入168例胃癌患者,经1∶1倾向性评分匹配后单孔组与多孔组各41例。单孔机器人组手术时间、装机时间及淋巴结清扫时间较长,但术后下床和排气更早、疼痛及瘢痕评分更低,并发症发生率两组差异无统计学意义。

要点

  • 单孔机器人远端胃癌根治术安全可行,R0切除率100%,无中转开腹。
  • 单孔组手术时间、装机及淋巴结清扫时间显著长于多孔组。
  • 单孔组术后疼痛轻、胃肠功能恢复快、瘢痕评分低,并发症相当。

核心结论

  • 国产单孔机器人辅助远端胃癌根治术安全可行,近期疗效与多孔机器人相当,在术后早期疼痛、胃肠功能恢复和外观方面有潜在优势。

研究设计与样本

  • 回顾性队列研究,纳入2023年9月至2025年7月河北医科大学第四医院外三科行机器人辅助胃癌手术的168例胃癌患者。
  • 多孔机器人组127例,单孔机器人组41例;采用1∶1最近邻倾向性评分匹配(卡钳值0.2),匹配后每组各41例。

主要发现

  • 匹配后两组均顺利完成手术,无中转开腹,R0切除率为100%。
  • 单孔组总手术时间246.0(52.0)min长于多孔组198.0(40.0)min(Z=-5.862,P<0.01)。
  • 单孔组装机时间19.0(3.0)min长于多孔组15.0(3.0)min(Z=-6.986,P<0.01)。
  • 单孔组淋巴结清扫时间158.0(42.0)min长于多孔组112.0(24.0)min(Z=-6.271,P<0.01)。
  • 单孔组术后首次下床活动时间1.0(0)d早于多孔组2.0(1.0)d(Z=-3.661,P<0.01),首次排气排便时间2.0(1.0)d早于3.0(1.0)d(Z=-2.499,P=0.012)。

关键数值与推荐

  • 消化道重建时间单孔组64.0(10.0)min与多孔组68.0(26.0)min差异无统计学意义(Z=-0.149,P=0.882)。
  • 术中出血量单孔组(25.1±10.7)ml与多孔组(24.6±11.4)ml差异无统计学意义(t=0.200,P=0.842)。
  • 淋巴结清扫数目单孔组(33.9±10.5)枚与多孔组(35.8±13.0)枚差异无统计学意义(t=-0.717,P=0.475)。
  • 并发症发生率单孔组9.8%(4/41)与多孔组12.2%(5/41)差异无统计学意义(P=1),两组均无Clavien-Dindo Ⅲ级及以上并发症。
  • 瘢痕评估量表评分单孔组(7.8±1.6)分低于多孔组(9.4±2.0)分(t=-3.893,P<0.01)。

临床怎么用

  • 单孔机器人可用于远端胃癌根治术,但术者需考虑其总手术时间、装机时间和淋巴结清扫时间较长。
  • 单孔机器人可能有助于减轻术后早期疼痛、加快下床活动和胃肠功能恢复,并改善瘢痕外观。

局限性

  • 本研究为单中心回顾性队列研究,样本量有限,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the short-term outcomes of distal radical gastrectomy for gastric cancer using domestically produced single-port and multi-port robotic systems. Methods: This retrospective cohort study included 168 patients with gastric cancer who underwent robot-assisted radical gastrectomy at the Third Department of Surgery, the Fourth Hospital of Hebei Medical University, between September 2023 and July 2025. The initial cohort included 115 males and 53 females, with an age of (60.1±10.5) years (range: 36 to 78 years). Among them, 127 patients underwent multi-port robotic surgery (MP group) and 41 underwent single-port robotic surgery (SP group). To minimize baseline differences, 1∶1 nearest-neighbor propensity score matching was performed (the caliper value was set to 0.2), yielding 41 matched patients in each group. Intraoperative variables and early postoperative outcomes were compared using the independent-samples t test, Mann-Whitney U test, chi-square test, or Fisher's exact test, as appropriate. Results: After matching, baseline characteristics were well-balanced. All procedures were successfully completed as R0 resections without conversion to open surgery. Compared with the MP group, the SP group had a longer total operative time (M(IQR) (246.0 (52.0) min vs. 198.0 (40.0) min, Z=-5.862, P<0.01), longer instrument setup time (19.0 (3.0) min vs. 15.0 (3.0) min, Z=-6.986, P<0.01), and longer lymph node dissection time (158.0 (42.0) min vs. 112.0 (24.0) min, Z=-6.271, P<0.01). Gastrointestinal reconstruction time, intraoperative blood loss, and the number of retrieved lymph nodes did not differ significantly between the two groups (all P>0.05). The SP group showed earlier postoperative ambulation (1.0 (0) d vs. 2.0 (1.0) d, Z=-3.661, P<0.01) and earlier recovery of bowel function (2.0 (1.0) d vs. 3.0 (1.0) d, Z=-2.499, P=0.012). No significant between-group differences were observed in time to first postoperative fluid intake (3.0 (1.0) d vs. 3.0 (1.0) d, Z=-1.278, P=0.201), time to first liquid diet (5.0 (1.0) d vs. 5.0 (1.0) d, Z=-1.012, P=0.312), or postoperative hospital stay (7.0 (2.0) d vs. 7.0 (3.0) d, Z=-0.442, P=0.842). The SP group reported lower Scar Assessment Scale scores ((7.8±1.6) points vs. (9.4±2.0) points, t=-3.893, P<0.01) and lower pain scores on postoperative days 1 to 3 (all P<0.05). Additionally, inflammatory markers (neutrophil-to-lymphocyte ratio and systemic immune-inflammation index) were significantly lower in the SP group on postoperative days 1 and 3 (all P<0.05). Postoperative complication rates were similar between the SP and MP groups (9.8% (4/41) vs. 12.2% (5/41), P=1). No Clavien-Dindo classification of surgical complications grade Ⅲ or higher complications occurred in either group. Conclusions: This study provides preliminary evidence that single-port robotic distal radical gastrectomy for gastric cancer is a safe and feasible approach. Short-term outcomes were generally comparable to those of multi-port robotic surgery,with potential advantages in early postoperative pain,recovery of gastrointestinal function,and cosmetic results. 目的: 比较国产单孔机器人和多孔机器人辅助远端胃癌根治术的近期疗效。 方法: 本研究为回顾性队列研究。回顾性分析2023年9月至2025年7月在河北医科大学第四医院外三科行机器人辅助胃癌手术的168例胃癌患者的临床和病理学资料。男性115例,女性53例;年龄(60.1±10.5)岁(范围:36~78岁)。其中多孔机器人组127例,单孔机器人组41例。采用1∶1最近邻倾向性评分匹配法(卡钳值为0.2)选取单孔机器人组和多孔机器人组各41例。分别通过独立样本t检验、Mann-Whitney U检验、χ2检验或 Fisher确切概率法比较匹配后两组患者的术中及术后近期恢复情况。 结果: 匹配后两组基线一致,均顺利完成手术,无中转开腹,R0切除率为100%。单孔机器人组总手术时间[M(IQR),246.0(52.0)min比198.0(40.0)min,Z=-5.862,P<0.01]、装机时间[19.0(3.0)min 比15.0(3.0)min,Z=-6.986,P<0.01]及淋巴结清扫时间[158.0(42.0)min 比112.0(24.0)min,Z=-6.271,P<0.01]均长于多孔机器人组;但两组消化道重建时间[64.0(10.0)min比 68.0(26.0)min,Z=-0.149,P=0.882]、术中出血量[(25.1±10.7)ml 比(24.6±11.4)ml,t=0.200,P=0.842]和淋巴结清扫数目[(33.9±10.5)枚比(35.8±13.0)枚,t=-0.717,P=0.475]的差异均无统计学意义。单孔机器人组术后首次下床活动时间[1.0(0)d比2.0(1.0)d,Z=-3.661,P<0.01]、首次排气排便时间[2.0(1.0)d比3.0(1.0)d,Z=-2.499,P=0.012]均早于多孔机器人组。术后首次饮水时间[3.0(1.0)d 比 3.0(1.0)d,Z=-1.278,P=0.201]、首次进流食时间[5.0(1.0)d比 5.0(1.0)d,Z=-1.012,P=0.312]及术后住院天数[7.0(2.0)d比7.0(3.0)d,Z=-0.442,P=0.842]相当。单孔机器人组患者与观察者瘢痕评估量表评分更低[(7.8±1.6)分比(9.4±2.0)分,t=-3.893,P<0.01],术后第1~3天疼痛评分更低(P值均<0.05),术后第1天和第3天的炎症指标中性粒细胞与淋巴细胞比率和全身免疫炎症指数评分更低(P值均<0.05)。两组并发症发生率分别为9.8%(4/41)和12.2%(5/41),差异无统计学意义(P=1),均无Clavien-Dindo并发症分级系统Ⅲ级及以上并发症发生。 结论: 本研究初步证实,国产单孔机器人辅助远端胃癌根治术安全可行,近期疗效与多孔机器人相当,可减轻患者术后早期疼痛、加快胃肠功能恢复,外观效果更佳。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Guo HH, Tian Y, Yang JX, et al. [A comparative analysis of the short-term efficacy of single-port and multi-port robotic distal gastrectomy for gastric cancer: a propensity score matched cohort study]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42056059. doi:10.3760/cma.j.cn112139-20251231-00621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。